Global Transcatheter Aortic Valve Implantation (TAVI) Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Transcatheter Aortic Valve Implantation (TAVI) Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Transcatheter Aortic Valve Replacement (TAVR), also referred to as Transcatheter Aortic Valve Implantation (TAVI) is a minimally invasive surgical procedure that repairs the valve without removing the old, damaged valve. Instead, it wedges a replacement valve into the aortic valve's place. Normally valve replacement method requires an open heart procedure with a sternotomy, in which the chest is surgically separated for the treatment. The TAVR procedures can be done through very small openings that leave all the chest bones in place.

Market Overview:


The latest research study on the global Transcatheter Aortic Valve Implantation (TAVI) market finds that the global Transcatheter Aortic Valve Implantation (TAVI) market reached a value of USD 6404.11 million in 2022. It’s expected that the market will achieve USD 15043.47 million by 2028, exhibiting a CAGR of 15.3% during the forecast period.

Simplify TF TAVI

The TF TAVI is the most commonly used type of access for TAVI. Since the current equipment uses 14-16 Fr sheath, the sheath size has been significantly reduced. This does not require surgical resection in most cases, reduces vascular complications and increases the proportion of patients eligible for TF TAVI.
In recent years, great progress has been made in simplifying TF TAVI. This includes a move toward conscious sedation rather than general anesthesia, percutaneous femoral access rather than surgical cut-down, temporary pacing through the left ventricular guidewire instead of inserting a right ventricular temporary pacing wire through a femoral vein sheath, dedicated vascular closure devices, operating without trans esophageal echo guidance and post-procedure care plans designed to promote early ambulation and discharge. This modern, minimalist TAVI method is quickly becoming the standard of care for simple cases.

Increasing adoption of minimally invasive therapies and increasing elderly population

Compared with traditional open-heart therapy, the continuous advancement of technology, the increasing demand for catheter-based minimally invasive surgery, and patients who choose effective therapies for rapid recovery are driving the market growth. The elderly are likely to receive this type of surgery because open heart surgery is too risky for them, and they cannot be operated on and cannot undergo surgical aortic valve replacement (SAVR).

Geographical challenges

Transcatheter Aortic Valve Implantation (TAVI) market is hindered owing to several factors. A prominent obstacle present in its growth involves a lack of expertise and a shortage of necessary manpower required to provide the treatments that involve the use of Transcatheter Aortic Valve Implantation (TAVI) in remote and underdeveloped regions. Owing to this, the market remains restrained geographically. Moreover, the high costs of manufacturing Transcatheter Aortic Valve Implantation (TAVI) devices might cause difficulties for small-scale healthcare centers to afford the required equipment compounds.

Region Overview:



Geographically, North America held the largest market share--61.22% in 2021.


Company Overview:


Edwards Lifesciences is one of the major players operating in the Transcatheter Aortic Valve Implantation (TAVI) market, holding a share of 62.95% in 2022.

Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.

Medtronic

Headquartered in Minneapolis, Minnesota, Medtronic plc is one of the world's largest medical technology companies, mainly providing life-long treatment programs for patients with chronic diseases.

Segmentation Overview:


As for product types, the Transfemoral Approach segment held the largest market share in 2021.

Application Overview:


The market's largest segment by application is the segment Aortic Stenosis, with a market share of 80.88% in 2021.

Key Companies in the global Transcatheter Aortic Valve Implantation (TAVI) market covered in Chapter 3:

Bracco (HLT) (Clinical-stage)
Meril Life Sciences
JenaValve Technology (Clinical-stage)
Edwards Lifesciences
Venus Medtech
JC Medical
Medtronic
MicroPort
Peijia Medical
Boston Scientific
Abbott

In Chapter 4 and Chapter 14.2, on the basis of types, the Transcatheter Aortic Valve Implantation (TAVI) market from 2018 to 2029 is primarily split into:

Transfemoral Approach
Transapical Approach

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Transcatheter Aortic Valve Implantation (TAVI) market from 2018 to 2029 covers:

Aortic Stenosis
Aortic Regurgitation
Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)